研究表明,在63%的患者中,塞马格卢提德可以阻止和逆转严重的脂肪肝疾病. Study shows semaglutide may halt and reverse severe fatty liver disease in 63% of patients.

一项新的研究表明,在Wegovy等药物中发现的酸,可能停止并逆转MASH,这是一种严重的脂肪肝病。 A new study suggests that semaglutide, found in drugs like Wegovy, may halt and reverse MASH, a severe form of fatty liver disease. 第3阶段的试验表明,62.9%的接受治疗的病人肝脏健康有所改善,而安慰剂组为34.3%。 The phase 3 trial showed that 62.9% of patients treated with semaglutide had improvements in liver health, compared to 34.3% in the placebo group. 该药物还导致体重下降和改善心脏健康,尽管美国尚未批准治疗MASH。 需要开展更多的研究,以证实其长期效益。 The drug also led to weight loss and improved heart health, though it is not yet approved for treating MASH in the U.S. More research is needed to confirm its long-term benefits.